BiotechTube
HOX Therapeutics

HOX Therapeutics

London, United Kingdom· Est.
hoxtherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

HOX Therapeutics is a UK-based, private biotech founded in 2019, operating in the preclinical stage. The company is singularly focused on developing targeted small molecule therapies for prostate cancer, a significant unmet medical need. Its early-stage status and limited public disclosure suggest it is likely in the target discovery and validation phase, building its scientific foundation and seeking initial funding.

OncologyProstate Cancer

Technology Platform

Focused on discovery of novel targeted small molecules for prostate cancer; specific platform details not publicly disclosed.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The significant unmet need in metastatic castration-resistant prostate cancer (mCRPC) presents a large market opportunity for novel targeted therapies.
Advances in understanding prostate cancer biology may reveal new, druggable targets.
The company's focused approach could make it an attractive partner or acquisition target for larger oncology-focused pharmaceutical companies.

Risk Factors

Extreme scientific and translational risk associated with novel, unvalidated targets in a preclinical-stage company.
High binary risk due to focused pipeline.
Significant financing risk in a competitive investment environment for early-stage biotech.
Intense competition from established players and numerous other biotechs in the prostate cancer space.

Competitive Landscape

The prostate cancer therapeutic landscape is highly competitive, featuring major pharmaceutical companies (e.g., Janssen, Pfizer, AstraZeneca, Bayer) and numerous biotechs developing next-generation hormonal agents, PARP inhibitors, radiopharmaceuticals, immunotherapies, and targeted therapies. HOX Therapeutics would need to demonstrate clear differentiation in mechanism, efficacy, or safety to succeed.

More companies in Oncology (General) →More companies in United Kingdom →